Esperion Therapeutis.Inc. sell platon
Summary
This prediction ended on 07.12.24 with a price of €3.39. With a performance of 3.35%, the SELL prediction by platon for Esperion Therapeutis.Inc. was trending in the wrong direction This prediction was marked as speculative and is excluded from platon's performance statistics.Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | - | - | - |
| iShares Core DAX® | 2.591% | 2.467% | 8.839% |
| iShares Nasdaq 100 | -0.915% | -6.458% | 24.933% |
| iShares Nikkei 225® | 0.145% | -8.773% | 47.385% |
| iShares S&P 500 | -0.367% | -1.220% | 21.667% |
Comments by platon for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.

